Recent FDA Approvals (through May 2011) related to Incivek, Victrelis, Edurant, Sutent, Argatroban injection, Afinitor, Tradjenta, Fusilev
Telaprevir (Incivek, Vertex) tablets were approved for a broad group of people with genotype 1 chronic hepatitis C (CHC) with compensated liver disease (some level of damage to the liver but the liver still functions), including cirrhosis.
Boceprevir (Victrelis, Merck) was approved for the treatment of genotype 1 CHC infection, in combination with peginterferon alfa and ribavirin, in adult patients (aged 18 years and older) with compensated liver disease, including cirrhosis, who are previously untreated or who have failed previous interferon and ribavirin therapy.
Rilpivirine (Edurant, Tibotec Therapeutics, a division of Centocor Ortho Biotech) in combination with other antiretroviral drugs was approved for the treatment of HIV-1 infection in adults who have never taken HIV therapy.
Argatroban injection (in sodium chloride) (Sandoz), the first ready-to-use alternative to concentrate formulation, was approved as an anticoagulant for the prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia.
Everolimus (Afinitor, Novartis) was approved for the treatment of patients with progressive neuroendocrine tumors located in the pancreas that cannot be removed by surgery or that have spread to other parts of the body.
Linagliptin (Tradjenta, Boehringer Ingelheim) tablets were approved, used with diet and exercise, to improve blood glucose control in adults with type 2 diabetes.
An expanded use of levoleucovorin (Fusilev, Spectrum Pharmaceuticals) was approved for patients with advanced metastatic colorectal cancer. This new indication of Fusilev where it will be used in combination with 5-fluorouracil, supplements the original 2008 FDA approval of the drug.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
Are PBMs Putting GLP-1 Drugs on Their Formularies?
October 11th 2024PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is uneven. What is needed is more data about whether these drugs can lower overall healthcare costs.
Read More